Fresenius Kabi
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, Fresenius Kabi sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Fresenius Kabi: 4 sponsored US clinical trials, 2 recruiting.
Fresenius Kabi sponsors 4 registered US clinical trials on ClinicalTrials.gov, 2 of them currently recruiting. 3 of these trials are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Malnutrition, with 2 trials.
Upper-quartile sponsor footprint
Fresenius Kabi sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Open and recent trials
4 total, page 1 of 1
Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
NCT06274788
Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients
NCT06049680
Safety and Efficacy Study to Compare Smoflipid and Intralipid 20% in Pediatric Patients of 3 Months to 16 Years of Age
NCT03563222
Phase 3 Study to Compare Safety and Efficacy of Smoflipid 20% to Intralipid 20% in Hospitalized Neonates and Infants
NCT02579265
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 3 | 1 |
| Phase 4 | 2 |
Where Fresenius Kabi enrollment is open (later-stage tilt)
2 recruiting of 4 indexed (50% open).
Phase mix: 3 late (III/IV) vs 0 early (I/II) (later-stage heavy).
Top condition: Malnutrition (2 trials), 6 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Fresenius Kabi: open-pipeline peers nationwide
Peers matched on 4 registered trials and 50% open enrollment, not the therapeutic-area sidebar.
Fresenius Kabi sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 trials (± recruiting share)
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors near 50% open enrollment (± trial volume)
- 1200 Pharma · 50% recruiting · 2 trials
- 1ST Biotherapeutics · 50% recruiting · 2 trials
- 3ive Labs · 50% recruiting · 2 trials
- 7 Hills Pharma · 50% recruiting · 2 trials
Related
What to do with this Fresenius Kabi page
4 registered trials is a research-attention snapshot, not an endorsement of Fresenius Kabi or any single study.
- 2 of Fresenius Kabi's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Malnutrition is the condition Fresenius Kabi studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Malnutrition trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Fresenius Kabi pipeline card: 4 registered trials from official public datasets.Report a data error.